The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium is accepting applications for their Cancer Drug Discovery Data Scientist Fellowship program. This one-year appointment in computationally-driven cancer drug discovery is part of a unique public-private partnership and will begin in early 2020. Scientists with doctoral degrees and backgrounds in biomedical or computational disciplines interested in cross-disciplinary training and collaboration are encouraged to apply.

Two optional Virtual Information Sessions will be held on October 15 and October 28 to provide potential applicants with an opportunity to ask questions about the fellowship program and application process.

Application submissions will be considered as they are received. Apply now.

Headquartered in San Francisco, CA, the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium was formed with the goal of transforming drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient centric model. Founding members of ATOM are the University of California, San Francisco (UCSF), GlaxoSmithKline (GSK), Lawrence Livermore National Laboratory (LLNL, for the Department of Energy), and Frederick National Laboratory for Cancer Research (FNLCR, for the National Cancer Institute).